Technology Bundle ID
NCI-E-018-2020

Parental A2780 Ovarian Cancer Cell Line and Derivative Cisplatin-resistant and Adriamycin-resistant A2780 Cell Lines

Applications
Research Materials
Co-Inventors
Nelson Ellmore (NCI)
Stuart Aaronson (NCI)
Development Status
Discovery (Lead Identification)
ICs
NCI

Ovarian cancer is one of the most common and lethal types of gynecological malignancies worldwide, accounting for approximately 295,000 new cases and 185,000 deaths annually. The high lethality rate is due to multiple reasons, including recurrence and the resistance of recurrent tumors to chemotherapy. Cell line models are crucial for preclinical cancer studies, to identify mechanisms of disease, to study drug resistance, and to screen for candidate therapeutics. 

Researchers at the National Cancer Institute (NCI), Laboratory of Cellular and Molecular Biology have derived a cell line, A2780, from a patient with metastatic ovarian adenocarcinoma who was not exposed to any anti-cancer agents before tumor extraction. This cell line forms tumors in nude mice and can be used to evaluate the effects of anti-cancer agents on ovarian cancer. Furthermore, cisplatin- (A2780CIS) and adriamycin- resistant (A2780ADR) derivatives have been developed by chronic exposure of the parental cell line to cisplatin and adriamycin, respectively. These lines show cross-resistance to other agents such as melphalan, vinblastine or irradiation, and can be used to study the molecular basis of drug resistance in ovarian cancer. 

NCI is seeking parties to non-exclusively license these ovarian cancer cell lines.

Commercial Applications
  • Research tool for drug screen and related preclinical studies of ovarian cancer therapeutics
  • Research tool for mechanistic studies of ovarian cancer such as the basis of drug resistance
Competitive Advantages
  • Well-characterized ovarian cancer cell lines
  • Parental A2780 may be used to generate other drug-resistant cell lines through exposure to low concentrations of other agents

Request More Info

Licensing Contact: